Skip to content
  • CMO Login
  • Collaborators Login
  • Home
  • Who We Are
    • About Us
  • What We Do
    • Programs & Services
    • Technologies
  • News
    • Press Releases
    • Publications
    • Events
  • Contact Us
    • Privacy Policies

Categories: Featured MK-6240 Articles

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging

Gold-standard diagnosis of Alzheimer’s disease (AD) relies on histopathological staging systems

Rates of regional tau accumulation in ageing and across the Alzheimer’s disease continuum: An AIBL 18F-MK6240 PET study

Background Tau PET imaging enables prospective longitudinal observation of the rate and location of tau accumulation in Alzheimer’s disease (AD)

Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer’s disease

The clinical and pathophysiological correlates of locus coeruleus (LC) degeneration in Alzheimer’s disease (AD) could be clarified using a method to index LC integrity in vivo, neuromelanin-sensitive MRI (NM-MRI)

Tau Imaging with 18F-MK6240 across the Alzheimer’s Disease spectrum

Tau deposition plays a critical role over cognition and neurodegeneration in Alzheimer’s disease (AD)

Comparing tau status determined via plasma pTau181, pTau231 and [ 18 F]MK6240 tau-PET

The threshold for positivity was 15.085 pg/mL for plasma pTau181 and 17.652 pg/mL for plasma pTau231

Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages

Tracking longitudinal tau tangles accumulation across the Alzheimer’s disease continuum is crucial to better understand the natural history of tau pathology and for clinical trials

Direct Comparison of the Tau PET Tracers 18 F-Flortaucipir and 18 F-MK-6240 in Human Subjects

Tau PET tracers exhibit varying levels of specific signal and distinct off-target binding patterns that are more diverse than amyloid PET tracers

Deep learning improves utility of tau PET in the study of Alzheimer’s disease

Positron emission tomography (PET) imaging targeting neurofibrillary tau tangles is increasingly used in the study of Alzheimer’s disease (AD), but its utility may be limited by conventional quantitative or qualitative evaluation techniques in earlier disease states

Recent Posts

  • Cerveau Technologies Inc. Signs Agreement with Roche to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
  • Cerveau Technologies, Inc. and Nihon Med-Physics Co., Ltd. Announce Manufacturing Service Agreement for [18F]MK-6240 in Japan
  • New PET imaging tracer helps spot signs of Alzheimer’s disease years before symptoms appear
  • FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
  • Cerveau Technologies, Inc. announces Formation of Scientific Advisory Board

Recent Comments

    Archives

    • March 2022
    • February 2022
    • June 2021
    • September 2020
    • May 2020
    • March 2020
    • December 2019
    • November 2019
    • September 2019
    • May 2019
    • March 2019
    • February 2019
    • December 2018
    • September 2018
    • August 2018
    • June 2018
    • May 2018
    • February 2018
    • January 2018
    • December 2017
    • November 2017
    • October 2017
    • September 2017
    • June 2017
    • May 2017
    • March 2017
    • February 2017
    • January 2017

    Categories

    • PRESS RELEASE
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    308 N. Peters Road Suite #201
    Knoxville, TN 37922

    (865) 868-3402

    info@cerveautechnologies.com

    © Copyright 2022 Cerveau Technologies. All Rights Reserved.

    • Privacy Policies

    Technology Web Design by Thomas Digital

    • Home
    • Who We Are
      • About Us
    • What We Do
      • Programs & Services
      • Technologies
    • News
      • Press Releases
      • Publications
      • Events
    • Contact Us
      • Privacy Policies